Ann: Appendix 4C - Quarterly, page-38

does know his stuff.

I don't personally believe it's all doom and gloom:
Still 13.5m in cash, and what appears to be a very good product (Neuronode). Some of the high staffing costs I.E appointments in the US should be one off.
The impact of COVID is an obvious one, yet, what are 'seasonality influences on applications in the USA?' (Is that just referencing 4th of July?)

I'm happy holding until more information comes to light, yet the renting model seems like a 'crap, better do something!, these damn things won't sell!'